Dicot Pharma publishes its annual report for 2024

Uppsala, Sweden, April 17, 2025. Today, the pharmaceutical company Dicot Pharma AB publishes the English version of its annual report for 2024.

For Dicot Pharma, 2024 was characterized by strong progress and significant study results where several important development milestones were passed. An oversubscribed rights issue has resulted in a good financial situation. The company notes that interest from both investors and medical experts is increasing.

The full annual report in English is available at www.dicotpharma.com/investor-relations/.

For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma’s business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. 

Dicot Pharma is listed on Nasdaq First North and has approximately 9,100 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.